Rebound Hyperbilirubinemia Study
Predictors of Rebound Hyperbilirubinemia After Phototherapy in Neonates
## Brief Summary
Neonatal hyperbilirubinemia is one of the most common causes of neonatal hospitalization and phototherapy treatment. Although phototherapy is highly effective, rebound hyperbilirubinemia following discontinuation of phototherapy may occur in some infants and may require repeat treatment. Early identification of neonates at risk for clinically significant rebound hyperbilirubinemia could help optimize discharge timing and reduce unnecessary hospital stay and repeat bilirubin testing.
This prospective observational study aims to evaluate the predictors of rebound hyperbilirubinemia after phototherapy discontinuation in neonates admitted to the NICU. Particular focus will be placed on the role of delta total serum bilirubin (ΔTSB), defined as the difference between the phototherapy threshold and the measured bilirubin level at the time of phototherapy discontinuation. Clinical, demographic, laboratory, hemolytic, feeding-related, and phototherapy-related variables will also be analyzed.
The primary outcome will be clinically significant rebound hyperbilirubinemia requiring repeat phototherapy within 24-48 hours after discontinuation of the initial phototherapy treatment. Secondary outcomes include rebound bilirubin levels, duration of hospitalization, and factors associated with repeat phototherapy.
Visão geral do estudo
Status
Descrição detalhada
## Detailed Description
Neonatal hyperbilirubinemia remains one of the leading causes of neonatal hospitalization worldwide. Phototherapy is the standard treatment for significant unconjugated hyperbilirubinemia and is highly effective in reducing serum bilirubin levels. However, a subset of neonates may develop rebound hyperbilirubinemia after discontinuation of phototherapy, occasionally requiring repeat phototherapy and prolonged hospitalization.
Current evidence regarding predictors of rebound hyperbilirubinemia remains limited, particularly in prospective NICU-based cohorts. Identification of infants at increased risk for clinically significant rebound hyperbilirubinemia may improve individualized monitoring strategies, optimize timing of discharge, and reduce unnecessary bilirubin measurements and hospital stay.
This prospective observational study will include neonates admitted to the NICU and treated with phototherapy for hyperbilirubinemia. Clinical and laboratory parameters associated with rebound hyperbilirubinemia will be evaluated. Special emphasis will be placed on delta total serum bilirubin (ΔTSB), defined as the difference between the phototherapy threshold recommended by current guidelines and the measured total serum bilirubin level at the time of phototherapy discontinuation.
Additional variables including gestational age, postnatal age at phototherapy initiation, feeding type, hemolytic risk factors, bilirubin kinetics, and phototherapy characteristics will also be analyzed. Rebound bilirubin measurements will be obtained within 24-48 hours after discontinuation of phototherapy according to unit protocol.
The primary objective is to determine predictors of clinically significant rebound hyperbilirubinemia requiring repeat phototherapy. Secondary objectives include evaluation of bilirubin rebound levels, hospitalization duration, and the association between phototherapy characteristics and rebound risk.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Dilek Kurnaz, M.D
- Número de telefone: +905556119280
- E-mail: drdilekkurnaz@gmail.com
Locais de estudo
-
-
Sultangazi
-
Istanbul, Sultangazi, Turquia (Türkiye), 34265
- University of Health Sciences, Haseki Training and Research Hospital
-
Contato:
- Dilek Kurnaz, M.D
- Número de telefone: 05556119280
- E-mail: drdilekkurnaz@gmail.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
The study population consists of neonates admitted to the NICU for neonatal hyperbilirubinemia and treated with phototherapy according to institutional protocols and current guideline-based phototherapy thresholds. Both standard and intensive phototherapy modalities may be used based on bilirubin levels, gestational age, and neurotoxicity risk factors.
Eligible neonates will be prospectively followed after discontinuation of phototherapy for evaluation of rebound hyperbilirubinemia and repeat phototherapy requirement. Clinical, laboratory, hemolytic, feeding-related, and phototherapy-related variables will be recorded and analyzed to identify predictors of clinically significant rebound hyperbilirubinemia.
Descrição
Inclusion Criteria:
- Neonates admitted to the NICU with neonatal hyperbilirubinemia Gestational age ≥35 weeks Requirement for phototherapy according to institutional protocol and current guideline-based phototherapy thresholds Receipt of standard and/or intensive phototherapy Availability of bilirubin measurements before, during, and after phototherapy Availability of rebound bilirubin measurement within 48 hours after phototherapy discontinuation Written informed consent obtained from parents or legal guardians, if required by the ethics committee
Exclusion Criteria:
- Major congenital anomalies Conjugated hyperbilirubinemia Neonates requiring exchange transfusion before completion of initial phototherapy Severe perinatal asphyxia Proven or suspected inborn errors of metabolism affecting bilirubin metabolism Significant congenital liver disease Neonates transferred to another center before completion of rebound bilirubin follow-up Missing or incomplete clinical or laboratory data Absence of rebound bilirubin measurement within 48 hours after phototherapy discontinuation Parents or legal guardians declining participation, if consent is required
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Neonates Receiving Phototherapy
This cohort includes neonates admitted to the NICU and treated with phototherapy for neonatal hyperbilirubinemia according to current institutional protocols and guideline-based phototherapy thresholds. Both standard and intensive phototherapy modalities may be used depending on bilirubin levels, gestational age, and neurotoxicity risk factors. Phototherapy is administered using Astek phototherapy devices and/or tunnel phototherapy systems, either as single-device or double-device therapy. Irradiance intensity may be adjusted according to clinical severity. Phototherapy is applied continuously except during feeding and routine care intervals. Serum bilirubin levels are monitored during and after phototherapy according to unit protocol. Rebound bilirubin measurements are routinely obtained after discontinuation of phototherapy, and additional measurements are performed in neonates considered at increased risk for rebound hyperbilirubinemia. Clinical, labo |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Clinically Significant Rebound Hyperbilirubinemia Requiring Repeat Phototherapy
Prazo: Within 48 hours after phototherapy discontinuation
|
Clinically significant rebound hyperbilirubinemia is defined as an increase in total serum bilirubin after discontinuation of initial phototherapy that reaches the guideline-based phototherapy threshold and requires initiation of repeat phototherapy.
|
Within 48 hours after phototherapy discontinuation
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- HASEKI-NICU-RHB-2026-01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Hiperbilirrubinemia Neonatal
-
Assumpta Solome NantumeDLR German Aerospace Center; Academic Model Providing Access to Healthcare (AMPATH)RecrutamentoMorbidade Neonatal | Complicação NeonatalQuênia
-
Istanbul University - CerrahpasaRecrutamentoAdaptação Neonatal | Termorregulação | Hipotermia NeonatalTurquia (Türkiye)
-
Hacettepe UniversityConcluídoCirurgia - Complicações | Morbidade Neonatal | Cirurgia NeonatalPeru
-
Gamze GocmenConcluídoCuidado neonatal Comforto neonatal Maldição de banho enrugadaPeru
-
Universidad Autonoma de Nuevo LeonConcluídoReadmissão Hospitalar | Morbidade Neonatal | Recém-nascido | Complicação Neonatal
-
Konya City HospitalConcluídoMorbidade Neonatal | Complicação NeonatalTurquia (Türkiye)
-
University College, LondonMinistry of Health and Child Welfare, Zimbabwe; Biomedical Research and Training... e outros colaboradoresRecrutamentoEncefalopatia Neonatal | Prematuridade | Convulsão Neonatal | Icterícia Neonatal | Sepse Neonatal | Morte Neonatal | Insuficiência Respiratória Neonatal | Hipoglicemia Neonatal | Distúrbio Neonatal | Hipotermia NeonatalZimbábue, Malauí
-
University Medical Centre LjubljanaRecrutamento
-
University Hospital PadovaDoctors with Africa - CUAMMConcluídoReanimação NeonatalEtiópia
-
Julie LefevereConcluídoMorbidade NeonatalBélgica